Upon reading Christopher Goodnow's recent Review article in Cell, which emphasized the overlapping role of somatic mutation in autoimmunity and cancer (Goodnow, 2007) , I was reminded of a graduate lecture course given by Professor Roderick MacLeod in 1995 at the University of Illinois. While introducing F.M. Burnet's clonal selection theory to our small class, Professor MacLeod mentioned Burnet's idea that germline and somatic mutations provide the inherited and stochastic mechanisms that disrupt tolerance and result in autoimmunity. In his Review article, Goodnow independently derives and extends this idea using compelling examples from more than 30 years of molecular and cellular immunology research that has accumulated since Burnet's insight. However, I recall during our class discussion that we did not find the potential impact of somatic mutation entirely satisfying. Three issues arose: sex, aging, and epitope spreading.
Autoimmune diseases commonly afflict the young and middle-aged. In contrast, the most significant risk factor for cancer is increasing age. According to the Surveillance Epidemiology and End Results (SEER) database, an analysis of data from 2000 to 2004 revealed that the median age for developing cancer in the United States is 67 years (Ries et al., 2007) . If the accumulation of somatic mutations is a major factor for developing autoimmunity, one would expect a similar median age of onset for autoimmune disease. One explanation for this apparent discrepancy is the reduction in lymphocyte production by the bone marrow and thymus as we enter middle age (Linton and Dorshkind, 2004) . This reduction in naive and potentially self-reactive lymphocytes could lead to substantially fewer opportunities for selfreactive rogue lymphocyte clones to arise due to somatic mutation in later life, subsequently reducing the incidence of autoimmune disease in older age groups (which Burnet also postulated; Burnet, 1972) . On the other hand, a recent summary of the median age of onset for autoimmune disease suggests that at least some autoimmune diseases have an older age of onset (>50 years) than previously thought (Cooper and Stroehla, 2003) . Somatic mutation may play a greater role in the pathogenesis of these autoimmune diseases.
Another confounding issue is the higher incidence of autoimmune diseases in females. There is no substantial evidence to suggest that the somatic mutation rate is greater in females. Instead, women appear to develop more robust immune responses compared to men; and animal models have shown that sex steroids affect the immune system and contribute to the development of autoimmunity (Whitacre, 2001) . Given that the regulation of sex steroid production is principally dictated by the X and Y chromosomes, the observed sex bias for autoimmune disease could be considered the result of this more basic genetic predisposition to be male or female, rather than the result of germline or somatic mutations.
Somatic mutations also do not readily explain epitope spreading in autoimmune diseases. Epitope spreading refers to the diversification of the immune response from a single epitope to multiple epitopes, found either on the same self-antigen or related self-antigens. Although difficult to observe in humans, animal models clearly show epitope spreading during the onset of autoimmune disease (Vanderlugt and Miller, 2002) . It seems unlikely that random somatic mutations would result in the sequential development of multiple rogue lymphocyte clones specific for different epitopes from the same target cell, as observed in animal models of Somatic Mutation and Autoimmunity autoimmune disease. One explanation is that a single rogue clone could initiate tissue damage releasing cryptic epitopes that are normally "hidden" from the immune system and for which tolerance is not established. Subsequent self-reactive clones specific for these cryptic epitopes would become active due to the local inflammatory milieu and would not necessarily require somatic mutations to avoid the immune system's mechanisms for maintaining self-tolerance. Furthermore, one recent study has demonstrated the hierarchical nature of the epitopes that precipitate autoimmune diabetes (Krishnamurthy et al., 2006) . If this is the case for other autoimmune diseases, then a rogue lymphocyte must recognize the primary self-antigen before epitope spreading can occur. This criterion would significantly reduce the pool of potential lymphocytes that could be affected by somatic mutations and that could initiate autoimmune disease. Notwithstanding, once the primary self-antigen is recognized and pathogenesis begins, then somatic mutations could lead to enhanced epitope spreading and the exacerbation of autoimmunity.
Finally, our class did not discuss infectious diseases, but in hindsight this point also could have been raised. It has been observed that the incidence of autoimmune diseases is escalating in developed countries (Bach, 2002) . It is doubtful that this escalation would be due to an increase in germline and/or somatic mutations within these populations. Rather, the parallel reduction in the incidence of infectious diseases in these countries may provide an alternative explanation. Although hotly debated, the hygiene hypothesis suggests that infections are beneficial for tempering the immune system and for preventing autoimmune disease (Bach, 2002) . Childhood infection may provide a stochastic protective mechanism in those individuals who have inherited alleles that predispose them to developing autoimmune disease. This of course does not rule out somatic mutation as a stochastic causative mechanism, but stimulation of the regulatory immune network due to infection may enhance peripheral tolerance when somatic mutations eventually give rise to rogue lymphocytes (Singh, 2000) . It is ironic that elimination of infectious diseases might leave the immune system free to attack the body. Therapies that stimulate the regulatory network during childhood, similar to vaccines that prevent infection, may enhance tolerance and prove more beneficial than targeting the elimination of rogue lymphocytes using pathway-specific drugs later in life.
None of these issues excludes the potential role of somatic mutation in the pathogenesis of autoimmune disease. Yet they do suggest that the impact of somatic mutations depends heavily on the interplay of other factors. It is curious that an increase in autoimmune diseases has not yet been observed for populations at-risk for increased somatic mutations due to radiation exposure from atomic bombs or nuclear reactor disasters (such as Hiroshima, Nagasaki, and Chernobyl; Imaizumi et al., 2006; Tronko et al., 2006) . As Burnet pointed out 35 years ago, "No biological phenomenon can ever be completely, or even adequately, described. There can, at best, only be a progressive improvement in the… practical usefulness of the working generalizations that can be produced" (Burnet, 1972) . In this regard, Goodnow's informative Review article revives a very useful concept that will hopefully generate new ideas and discussion not just in the laboratory and clinic, but also in the classroom. 
